SLC7A11 and glioblastoma: Recent evidence has spotlighted the glutamate-cystine exchanger xCT (SLC7A11, system Xc−) as a potential drug target in treating glioblastoma.7,8 The xCT system represents a key player in glutamate, cystine and glutathione metabolism in most cells.2,9 xCT is highly expressed in astrocytes and has also been found in glioblastoma promoting chemotherapeutic resistance.10 Moreover, xCT levels are causally linked with the malignancy grade of glioblastoma.7,11 Apoptosis is a common form of programmed cell death that can be triggered by chemotherapeutic drugs via the intrinsic or extrinsic pathways.